Investor
Merck Global Health Innovation Fund
2$1.6bn$1.05bn0
Startups backed by Merck Global Health Innovation Fund that were acquired: 2 exits so far, with the buyer, the price where disclosed and every source.
Photo: Goldmund100 / Wikimedia Commons, CC BY-SA 3.0argenx agrees to buy Unnatural Products for $550 million upfront to add oral peptide drug discovery
The two companies had worked together for more than two years, and argenx already owned part of the Santa Cruz biotech. The full price could reach about $1.15 billion if development and regulatory milestones are met.
$550m$77mSeries BCorporate
Latest in Merck Global Health Innovation FundBoston · Healthtech & bioRoche agrees to buy digital pathology company PathAI for up to $1.05 billion

All Merck Global Health Innovation Fund exitsOpen tracker →
argenx → Unnatural Products$550m$250m–1bnRoche → PathAI$1.05bn$1bn+